MedTrace Logo

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2012-05-18

Study results available
· View outcomes & findings →

Summary

This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.

Conditions

  • Alzheimer Disease

Interventions

DRUG

florbetapir F 18

IV injection, 370MBq (10mCi), single dose

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · Avid Radiopharmaceuticals

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01564706 on ClinicalTrials.gov